Anticipation builds with Q126 results

Immix Biopharma has reported its Q126 results, highlighting continued execution across the NXC-201 CAR-T clinical programme in relapsed/refractory amyloid light chain amyloidosis (r/r ALA), alongside a strengthened balance sheet after the company’s December 2025 financing. During Q126, Immix continued to make progress in the NEXICART-2 trial for NXC-201 in r/r ALA. Importantly, patient enrolment was completed in March 2026, and the company is on track to deliver the final readout in Q326, representing a significant upcoming potential catalyst. Should the results be supportive, management plans to submit a biologics licence application (BLA) to the FDA by end-2026. Our valuation for Immix adjusts to $786.7m or $14.5 per share (from $786.5...